ISONIAZID by Eli Lilly and Company is mechanism of action isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
Isoniazid is a small-molecule oral tablet indicated for tuberculosis treatment, developed by Eli Lilly. It inhibits mycoloic acid synthesis in the bacterial cell wall, making it bactericidal against actively growing Mycobacterium tuberculosis. The product is currently in pre-launch stage as an NDA.
Pre-launch stage indicates early commercial infrastructure building with opportunities for launch planning, market access, and field team development.
Mechanism of Action Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Resistance Resistance to…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Worked on ISONIAZID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Isoniazid at pre-launch offers exposure to early-stage product commercialization, regulatory approval processes, and market positioning in the global TB treatment space. Career growth depends on successful launch execution and the product's ability to differentiate in an established therapeutic category.